A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Ustekinumab (Primary)
- Indications Spondylarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 11 Aug 2017 Planned End Date changed from 9 Dec 2019 to 1 Sep 2017.
- 11 Aug 2017 Planned primary completion date changed from 10 Jan 2018 to 1 Sep 2017.
- 15 Jun 2017 Status changed from recruiting to active, no longer recruiting.